QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk

Impact · against what's priced in

QuidelOrtho faces a significant near-term headwind as a milder respiratory season led to a 43.3% revenue drop in that segment and a swing to an adjusted loss. While market share remains stable, the volatility of respiratory demand is creating immediate margin compression and inventory inefficiencies.

QDEL−0.70

No priced-in read yet

In context

The company reported a first-quarter adjusted loss of 4 cents per share and a 43.3% year-over-year drop in respiratory revenue to $67.9 million, driven by a 30% decline in influenza-like illness visits.

Read from the article alone

• healthcare▲2%
• earnings
• QDEL
• diagnostics
• medical devices
• respiratory testing
• revenue decline

Top 1 mover · tap to explore